Drugs / GEN1047
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05180474 | Dec 2021 → Mar 2026 | breast cancer, endometrial cancer, non-small cell squamous lung carcinoma, ovarian cancer | Genmab | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GEN1047 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05180474 ↗ |
| Action | Deplete | “induces T-cell mediated cytotoxicity of B7H4-positive tumor cells” NCT05180474 ↗ |
| Route | Intravenous | “GEN1047 will be administered as an intravenous infusion.” NCT05180474 ↗ |